SCHEMBL717606

SCHEMBL717606

CCOC(=O)c1cccc(N)c1C

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.74
HSD17B10 Q99714 8/20 0.74
TSHR P16473 2/20 0.63
CDC25B P30305 4/20 0.57
MAPT P10636 4/20 0.50
ALOX15 P16050 3/20 0.50
RAB9A P51151 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
GAA P10253 2/20 0.50
HPGD P15428 2/20 0.50
KDM4E B2RXH2 2/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
CA14 Q9ULX7 1/20 0.50
POLB P06746 1/20 0.50
CYP1A2 P05177 3/20 0.49
LMNA P02545 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19994753 0.88 ALDH1A1 (0.64) ALDH1A1HSD17B10TSHRCDC25BRAB9A
SCHEMBL2925689 0.86 ALDH1A1 (0.74) ALDH1A1HSD17B10TSHRCDC25BMAPT
Ethyl Anthranilate SCHEMBL30055126 0.85 ALDH1A1 (1.00) ALDH1A1HSD17B10TSHRCDC25BMAPT
Ethyl Anthranilate SCHEMBL34474 0.85 ALDH1A1 (1.00) ALDH1A1HSD17B10TSHRCDC25BMAPT
SCHEMBL2894636 0.84 ALDH1A1 (0.72) ALDH1A1HSD17B10TSHRCDC25BMAPT
SCHEMBL177310 0.84 ALDH1A1 (0.72) ALDH1A1HSD17B10TSHRCDC25BMAPT
SCHEMBL55681 0.84 ALDH1A1 (0.61) ALDH1A1HSD17B10TSHRCDC25BMAPT
Ethyl Anthranilate SCHEMBL1396081 0.84 ALDH1A1 (0.96) ALDH1A1HSD17B10TSHRCDC25BMAPT
Ethyl Anthranilate SCHEMBL7560547 0.84 ALDH1A1 (0.96) ALDH1A1HSD17B10TSHRCDC25BMAPT
SCHEMBL9078373 0.83 TSHR (0.65) ALDH1A1HSD17B10TSHRCDC25BRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116649347-A Compound, solenopsis invicta repellent prepared from compound and combination of compound and solenopsis invicta repellent and application of solenopsis invicta repellent 中国人民解放军海军军医大学 2023-08-29 CN disclosed
CN-115974586-A Colorful heat-preservation soft porcelain and preparation method thereof 颜如玉 2023-04-18 CN disclosed
EP-3470396-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. (US) 2019-04-17 EP disclosed
EP-2816040-B1 Process for the production of CCR2 receptor antagonists and intermediates thereof CENTREXION THERAPEUTICS CORP (US) 2018-10-17 EP disclosed
CN-107663202-A 3- (ureido-methyl) -4-aryl-pyridine derivative, preparation method thereof and application thereof as anti-liver cancer drug 西华大学 2018-02-06 CN disclosed
US-9827244-B2 Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease F. HOFFMANN-LA ROCHE AG (CH) 2017-11-28 US disclosed
CN-104066718-B Substituted benzene compounds EPIZYME股份有限公司 2017-08-29 CN disclosed
EP-3166951-A1 DIHYDROPYRIDOPYRAZINE-1,8-DIONES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF VIRAL DISEASES Savira Pharmaceuticals GmbH (AT) 2017-05-17 EP disclosed
EP-3165520-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme Inc (US) 2017-05-10 EP disclosed
US-20170000788-A1 Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease HOFFMANN LA ROCHE (CH) 2017-01-05 US disclosed
CN-1082790-C Herbicides RHONE POULENE AGRICULTURE LTD (GB) 2002-04-17 CN disclosed
EP-1180514-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2002-02-20 EP disclosed
EP-0874846-A1 PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION Novartis AG (CH) 1998-11-04 EP disclosed
EP-0625505-B1 2-Cyano-1,3-dione derivatives and their use as herbicides RHONE POULENC AGRICULTURE (GB) 1998-10-28 EP disclosed
WO-1997016452-A1 PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION NOVARTIS AG (CH) 1997-05-09 WO disclosed
CN-1100261-A Herbicides RHONE POULENC AGRICULTURE (GB) 1995-03-22 CN disclosed
EP-0625505-A2 2-Cyano-1,3-dione derivatives and their use as herbicides RHONE POULENC AGRICULTURE LTD. (GB) 1994-11-23 EP disclosed
US-4493843-A Indole and indoline carboxylic acid compounds and method of use MAY & BAKER LIMITED (GB) 1985-01-15 US disclosed
EP-0042298-B1 INDOLE AND INDOLINE DERIVATIVES MAY & BAKER LIMITED (GB) 1984-09-12 EP disclosed
EP-0042298-A1 Indole and indoline derivatives MAY & BAKER LIMITED (GB) 1981-12-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170000788-A1 Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease MME, CAPRIN1, XPNPEP1 ALDH1A1 3290/4885HSD17B10 1295/4885TSHR 4565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.